The factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved a major talking point at an event on the fringes of this year’s ESMO conference
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh